Blog Posts
Rahul Banerjee: Optimal MRD-based Endpoint in Multiple Myeloma
Rahul Banerjee, Smith Giri and Luciano Costa

Rahul Banerjee: Optimal MRD-based Endpoint in Multiple Myeloma

Rahul Banerjee, Assistant Professor at Fred Hutchinson Cancer Center at the University of Washington, shared a post on X about recent article by Luciano J Costa, Smit Giri et al.:

“As usual, masterfully written (no pun intended) by Luciano J Costa, Smit Giri et al.

sMRD- at 10^-5 performed better than sMRD- at 10^-6. Turned many heads at ASH24. May be small n, or:

Maybe sMRD ≤10^-5 catches the most patients and gives us the prognostic info we need!”

Rahul Banerjee

Title: Optimal MRD-based end point to support response-adapted treatment cessation in newly diagnosed multiple myeloma

Authors: Smith Giri, Binod Dhakal, Natalie Callander, Eva Medvedova, Kelly Godby, Bhagirathbhai Dholaria, Susan Bal, Gayathri Ravi, Saurabh Chhabra, Rebecca Silbermann, Luciano Costa.

Read Full Article.

More posts featuring Rahul Banerjee on OncoDaily.

Bhagirathbhai Dholaria Binod Dhakal cancer Eva Medvedova Gayathri Ravi Kelly Godby Luciano Costa multiple myeloma Natalie Callander OncoDaily Oncology Rahul Banerjee Rebecca Silbermann Saurabh Chhabra Smith Giri Susan Bal